Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Multistep molecular trajectory during monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells

Yu Inoue, Yuji Shimura, Yui Niiyama-Uchibori, Shotaro Chinen, Takahisa Nakamura, Haruya Okamoto, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Junya Kuroda

Blood (2025) 146 (Supplement 1): 7091.

https://doi.org/10.1182/blood-2025-7091

Published: 2025

Journal Articles

Non-infectious fever predicts poor survival in azacitidine-treated high-risk, but not low-risk, myelodysplastic syndromes：a multicenter real-world cohort study (KOTOSG)

Takahisa Nakamura, Haruya Okamoto, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Hiroto Kaneko, Mitsushige Nakao, Ryoichi Takahashi, Shin-ichi Fuchida, Daichi Nishiyama, Yuri Kamitsuji, Hitoji Uchiyama, Eri Kawata, Nobuhiko Uoshima, Junya Kuroda

Blood (2025) 146 (Supplement 1): 3850.

https://doi.org/10.1182/blood-2025-3850

Published: 2025

Journal Articles

Celmods potently inhibit m-MDSC induction by targeting IL-10 and MIF in multiple myeloma

Yui Niiyama-Uchibori, Yu Inoue, Shotaro Chinen, Takahisa Nakamura, Hiroaki Nagata, Haruya Okamoto, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Junya Kuroda

Blood (2025) 146 (Supplement 1): 7447.

https://doi.org/10.1182/blood-2025-7447

Published: 2025

Journal Articles

A prognostic model integrating disease‑ and patient‑oriented factors identifies poor‑outcome patients with low‑risk MDS: A multicenter real‑world cohort study (KOTOSG)

Blood (2025) 146 (Supplement 1): 5633.

https://doi.org/10.1182/blood-2025-5633

Published: 2025

Journal Articles

Efficacy of upfront blinatumomab combined with reduced-intensity chemotherapy for newly diagnosed adult Philadelphia chromosome–negative B-lineage acute lymphoblastic leukemia: Interim analysis of two prospective studies of JSCT ALL/MRD2023 and ALL/MRD2019 in Japan

Blood (2025) 146 (Supplement 1): 5116.

https://doi.org/10.1182/blood-2025-5116

Published: 2025

Journal Articles

Outcomes of relapsed or refractory mature T/NK-cell lymphomas in the era of novel agents: A nationwide observational Study in Japan

Blood (2025) 146 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2025-1865

Published: 2025

Journal Articles

The Anti-Myeloma Efficacy of TAS0612, a Triple Inhibitor of RSK, AKT, and S6K, and Itssynergistic Combination with Venetoclax in Multiple Myeloma Irrespective of Cytogeneticabnormalities

Haruya Okamoto, Shinsuke Mizutani, Taku Tsukamoto, Yoko Katsuragawa-Taminishi, Yuka Kawaji-Kanayama, Kentaro Mizuhara, Ayako Muramatsu, Reiko Isa, Takahiro Fujino, Yuji Shimura, Koji Ichikawa, Junya Kuroda

Blood (2024) 144 (Supplement 1): 4178.

https://doi.org/10.1182/blood-2024-199695

Published: 2024

Journal Articles

TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, Is a Promising Anti-Myeloma Agent Regardless of Types of Cytogenetic/Genetic Abnormality

Haruya Okamoto, Shinsuke Mizutani, Taku Tsukamoto, Yoko Katsuragawa-Taminishi, Reiko Isa, Kentaro Mizuhara, Ayako Muramatsu, Yuka Kawaji-Kanayama, Takahiro Fujino, Yuji Shimura, Junya Kuroda

Blood (2023) 142 (Supplement 1): 3313.

https://doi.org/10.1182/blood-2023-174157

Published: 2023

Journal Articles

The Universal Antitumor Activity of TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, in B-Cell Lymphomas Regardless of Disease Subtype

Yoko Katsuragawa-Taminishi, Shinsuke Mizutani, Yuka Kawaji-Kanayama, Akio Onishi, Haruya Okamoto, Reiko Isa, Kentaro Mizuhara, Ayako Muramatsu, Takahiro Fujino, Taku Tsukamoto, Yuji Shimura, Masafumi Taniwaki, Aya Miyagawa-Hayashino, Eiichi Konishi, Junya Kuroda

Blood (2023) 142 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2023-173485

Published: 2023

Journal Articles

The Activation Status of RSK2, but Not PDPK1 and AKT, Associates with the Prognosis of Diffuse Large B Cell Lymphoma

Akio Onishi, Aya Miyagawa-Hayashino, Kentaro Mizuhara, Ayako Muramatsu, Haruya Okamoto, Yuka Kawaji-Kanayama, Yoko Katsuragawa-Taminishi, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Eiichi Konishi, Junya Kuroda

Blood (2023) 142 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2023-184365

Published: 2023

Journal Articles

Mir-106a-5p and Mir-146a-5p Delivered By Tumor-Derived Exosomes Promote the Induction of Myeloid-Derived Suppressor Cells from Normal Peripheral Blood Mononuclear Cells in Multiple Myeloma

Kentaro Mizuhara, Yuji Shimura, Taku Tsukamoto, Akinori Kanai, Saeko Kuwahara-Ota, Junko Yamaguchi, Ayako Muramatsu, Haruya Okamoto, Yoko Katsuragawa-Taminishi, Yuka Kawaji-Kanayama, Reiko Isa, Shinsuke Mizutani, Toshiya Inaba, Junya Kuroda

Blood (2022) 140 (Supplement 1): 9949–9950.

https://doi.org/10.1182/blood-2022-160408

Published: 2022

Journal Articles

Nutritional and Cytogenetic Assessment Predicts Favorable Response to Azacitidine Monotherapy for Myelodysplastic Syndromes

Haruya Okamoto, Yu Inoue, Akihiro Miyashita, Yuka Kawaji-Kanayama, Shotaro Chinen, Takahiro Fujino, Taku Tsukamoto, Yuji Shimura, Shinsuke Mizutani, Hiroto Kaneko, Saeko Kuwahara, Shin-ichi Fuchida, Daichi Nishiyama, Koichi Hirakawa, Junya Kuroda

Blood (2022) 140 (Supplement 1): 12321–12322.

https://doi.org/10.1182/blood-2022-157863

Published: 2022

Journal Articles

Genome-Wide Analysis of BRD4-Targets Reveals the Therapeutic Relevance of Simultaneous Targeting of BCR Pathway and IKZF-MYC Axis in Mantle Cell Lymphoma

Junya Kuroda, MD PhD, Taku Tsukamoto, MD PhD, Shingo Nakahata, Kazuhiro Morishita, MD PhD, Ryuichi Sato, Akinori Kanai, PhD, Toshiya Inaba, Masakazu Nakano, Kei Tashiro, Masafumi Taniwaki, MD PhD

Blood (2018) 132 (Supplement 1): 4100.

https://doi.org/10.1182/blood-2018-99-109982

Published: 2018

Journal Articles

A New Prediction System for Platelet Recovery after Autologous Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphomas

Junko Yamaguchi, MD, Yoshiaki Chinen, MD PhD, Hitoji Uchiyama, MD PhD, Nobuhiko Uoshima, MD PhD, Hiroto Kaneko, MD PhD, Mitsushige Nakao, MD PhD, Taku Tsukamoto, MD PhD, Yuji Shimura, MD PhD, Tsutomu Kobayashi, MD PhD, Shigeo Horiike, MD PhD, Junya Kuroda, MD PhD

Blood (2018) 132 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2018-99-112864

Published: 2018

Journal Articles

More Somatic Mutations Including Those in the Aid-Motif with High-Risk, Histologically Non-Transformed Follicular Lymphomas

Taku Tsukamoto, MD, Masakazu Nakano, PhD, Ryuichi Sato, Hiroko Adachi, Miki Kiyota, MD PhD, Satoru Yasukawa, MD PhD, Shotaro Tatekawa, MD, Yoshiaki Chinen, MD PhD, Hisao Nagoshi, MD PhD, Shinsuke Mizutani, MD PhD, Yuji Shimura, MD PhD, Mio Yamamoto-Sugitani, MD PhD, Tsutomu Kobayashi, MD PhD, Tomohiko Taki, MD PhD, Shigeo Horiike, MD PhD, Akio Yanagisawa, MD PhD, Masafumi Taniwaki, MD PhD, Kei Tashiro, MD PhD, Junya Kuroda, MD PhD

Blood (2016) 128 (22): 4116.

https://doi.org/10.1182/blood.V128.22.4116.4116

Published: 2016

Journal Articles

The Curative Potential Of Fludarabine125, Melphalan100, and Busulfan4 As a Conditioning Regimen For Myeloid Malignancies Of Elderly Patients

Tomoaki Ueda, MD, Aki Sato, M.D., Kazuya Sakai, MD, Hiroyuki Muranushi, MD, Yusuke Okamoto, MD, Taku Tsukamoto, MD, Hiroyuki Sugiura, MD, Hiroyuki Matsui, MD, Tomoyasu Jo, MD, Kazuya Okada, MD, Takeshi Maeda, MD, Tatsuhito Onishi, MD, Akane Kunitomi, MD, PhD, Yasunori Ueda, MD, PhD

Blood (2013) 122 (21): 4551.

https://doi.org/10.1182/blood.V122.21.4551.4551

Published: 2013

Journal Articles

Pre-Treatment WT1 mRNA Expression Level In Peripheral Blood Predicts Response and Overall Survival Of Myelodysplastic Syndrome Patients In The Azacitidine Era

Tomoyasu Jo, MD, Kazuya Sakai, MD, Hiroyuki Muranushi, MD, Yusuke Okamoto, MD, Taku Tsukamoto, MD, Hiroyuki Sugiura, MD, Hiroyuki Matsui, MD, Tomoaki Ueda, MD, Kazuya Okada, MD, Takeshi Maeda, MD, Tatsuhito Onishi, MD, Akane Kunitomi, MD, PhD, Yasunori Ueda, MD, PhD

Blood (2013) 122 (21): 1528.

https://doi.org/10.1182/blood.V122.21.1528.1528

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Multistep molecular trajectory during monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells

Non-infectious fever predicts poor survival in azacitidine-treated high-risk, but not low-risk, myelodysplastic syndromes：a multicenter real-world cohort study (KOTOSG)

Celmods potently inhibit m-MDSC induction by targeting IL-10 and MIF in multiple myeloma

A prognostic model integrating disease‑ and patient‑oriented factors identifies poor‑outcome patients with low‑risk MDS: A multicenter real‑world cohort study (KOTOSG)

Efficacy of upfront blinatumomab combined with reduced-intensity chemotherapy for newly diagnosed adult Philadelphia chromosome–negative B-lineage acute lymphoblastic leukemia: Interim analysis of two prospective studies of JSCT ALL/MRD2023 and ALL/MRD2019 in Japan

Outcomes of relapsed or refractory mature T/NK-cell lymphomas in the era of novel agents: A nationwide observational Study in Japan

The Anti-Myeloma Efficacy of TAS0612, a Triple Inhibitor of RSK, AKT, and S6K, and Itssynergistic Combination with Venetoclax in Multiple Myeloma Irrespective of Cytogeneticabnormalities

TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, Is a Promising Anti-Myeloma Agent Regardless of Types of Cytogenetic/Genetic Abnormality

The Universal Antitumor Activity of TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, in B-Cell Lymphomas Regardless of Disease Subtype

The Activation Status of RSK2, but Not PDPK1 and AKT, Associates with the Prognosis of Diffuse Large B Cell Lymphoma

Mir-106a-5p and Mir-146a-5p Delivered By Tumor-Derived Exosomes Promote the Induction of Myeloid-Derived Suppressor Cells from Normal Peripheral Blood Mononuclear Cells in Multiple Myeloma

Nutritional and Cytogenetic Assessment Predicts Favorable Response to Azacitidine Monotherapy for Myelodysplastic Syndromes

Genome-Wide Analysis of BRD4-Targets Reveals the Therapeutic Relevance of Simultaneous Targeting of BCR Pathway and IKZF-MYC Axis in Mantle Cell Lymphoma

A New Prediction System for Platelet Recovery after Autologous Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphomas

More Somatic Mutations Including Those in the Aid-Motif with High-Risk, Histologically Non-Transformed Follicular Lymphomas

The Curative Potential Of Fludarabine125, Melphalan100, and Busulfan4 As a Conditioning Regimen For Myeloid Malignancies Of Elderly Patients

Pre-Treatment WT1 mRNA Expression Level In Peripheral Blood Predicts Response and Overall Survival Of Myelodysplastic Syndrome Patients In The Azacitidine Era

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only